1) Mild to Moderate Asthma Study

Clinical Trial Description: We are studying an experimental nutritional drink for the treatment of asthma in children. The purpose of this study is to determine whether this nutritional drink can increase asthma free days by assessing the frequency of daily asthma symptoms in children with mild to moderate persistent asthma.

Dr. Stanley Szefler, Principal Investigator / Kelli Brown-Engelhardt, Study Coordinator

To be eligible you must be:

• Ages 6-14 with mild to moderate asthma
• Must not be on an inhaled steroid
• Must have symptoms three or more times a week often requiring rescue medication
• And can participate in the study for 4 months with 8 visits occurring every one to two weeks

Qualified participants may receive physical examinations, ECG's, lung function tests, skin testing and study drug at no cost. In addition, participants who qualify to participate in the study will be financially compensated.

2) Moderate to Severe Uncontrolled Allergic Asthma Study

Clinical Trial Description: This study is designed to demonstrate one-year efficacy and safety data for subcutaneous (SQ) Xolair®, compared to placebo in children 6 to <12 years with moderate to severe persistent asthma, who have inadequate asthma control despite treatment with medium to high dose inhaled corticosteroids.

Dr. Henry Milgrom, Principal Investigator / Kelli Brown-Engelhardt, Study Coordinator

To be eligible you must be:

• Between the ages of 6–11 with moderate to severe allergic asthma
• Must be on an inhaled steroid with at least four days of symptoms per week
• And be willing to participate in the study for 19 months with visits either every two weeks or every four weeks

Qualified participants may receive physical examinations, ECG's, lung function tests, skin testing and study drug at no cost. In addition, participants who qualify to participate in the study will be financially compensated.

3) Peanut Allergy Study

Clinical Trial Description: Peanut allergy is the most common food allergy in the United States, affecting 1.5 million people. We are currently conducting a research study that is investigating the efficacy of Xolair® in reducing the risk of peanut-induced allergic reactions. Xolair is designed to bind to the IgE in the body and lower the risk of allergic reactions. IgE is a protein that has been shown to play an important part in allergic reaction. This study will test your reaction to peanuts after 24 weeks of treatment with Xolair or placebo (a substance that contains no medication).

Dr. Donald Leung, Principal Investigator / Amanda Calhoun, Study Coordinator

To be eligible you must be:

• Be between the ages of 6–75
• Have a history of severe, allergic reaction to peanuts
• React to peanut flour but not wheat (placebo) flour during the first Oral Food Challenge (OFC)
• Have a positive skin test to peanut or detectable serum peanut-specific IgE level
• Be able to swallow pills

Duration: 38 weeks participation in study with approximately 16 visits to the clinic.

Qualified participants may receive physical examinations, ECG's, lung function tests, skin testing, and study drug at no cost. In addition, participants who qualify to participate in the study will be financially compensated.